// App-Quantinova.ai

e24029 : Methylomes variation to predict exemestane resistance in advanced breast cancer.

Researchers

Presenter

  • Xiao-Ran Liu

Principal Investigators

  • Ru-Yan Zhang

  • Hao Gong

  • Hope S. Rugo

  • Jian Tie

  • Lingbo Chen

  • Yuan Fu

  • Jianwei Che

  • Bin Shao

  • Feng-Ling Wan

  • Wei-yao Kong

  • Guo-hong Song

  • Han-fang Jiang

  • Guo-bing Xu

  • Huiping Li

Medical Centers

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Department of breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

  • M3 Genomics, Inc., Guangzhou, China

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

  • China

Companies

  • M3 Genomics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Exemestane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved